New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis
Webinar Recorded on Aug. 11, 2020
Sponsored by Scipher Medicine
Drug costs for targeted autoimmune diseases account for a large and growing proportion of pharmacy spend per patient. Despite most rheumatoid arthritis patients receiving anti-TNF therapies as their first targeted treatment, 2 in 3 patients have an inadequate response to these drugs. Even after patients fail treatment, many still cycle through multiple anti-TNF therapies before trying something different. The resulting healthcare waste is enormous: with annual sales of $33 billion, anti-TNF therapies are the world’s largest selling drug class.
PrismRA® from Scipher Medicine is a groundbreaking molecular signature test now available at the request of commercial payers and rheumatologists seeking relief from this pain point in reimbursement and prescribing. PrismRA® identifies patients who are unlikely to have an adequate response to anti-TNF therapies with 90% accuracy. Once stratified, clinicians can initiate an alternative mechanism of action, increasing the number of patients who respond to initial RA therapy by 40%.
- James T. Kenney, MBA, RPh, President, JTKENNEY, LLC
- Alif Saleh, CEO, Scipher Medicine
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.